阿奇霉素联合甲泼尼龙治疗难治性支原体肺炎的临床效果

Clinical effect of Azithromycin combined with methylprednisolone in the treatment of refractory Mycoplasma pneumonia

目的探讨阿奇霉素联合甲泼尼龙治疗难治性支原体肺炎的临床效果。方法选取2016年6月~2019年6月我院收治的46例难治性支原体肺炎患者作为研究对象,按随机数字表法进行分组。参照组23例患者采用阿奇霉素治疗,研讨组23例患者采用阿奇霉素联合甲泼尼龙治疗,对两组患者的超敏C反应蛋白(hs-CRP)、血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)等血清炎症因子指标,以及T淋巴细胞总数(CD3+)、阴性T细胞(CD4+)、阳性T细胞(CD8+)及阴性T细胞与阳性T细胞之比(CD4+/CD8+)外周血指标进行比较分析,同时观察两组患者的临床疗效。结果两组患者治疗后hs-CRP、TNF-α、IL-6水平低于本组治疗前,差异有统计学意义(P<0.05);研讨组患者治疗后hs-CRP、TNF-α、IL-6水平低于参照组,差异有统计学意义(P<0.05)。两组患者治疗后CD3+、CD4+、CD4+/CD8+水平高于本组治疗前,CD8+水平低于本组治疗前,差异有统计学意义(P<0.05);研讨组患者治疗后CD3+、CD4+/CD8+、CD4+水平高于参照组,CD8+水平低于参照组,差异有统计学意义(P<0.05)。研讨组患者治疗总有效率高于参照组,差异有统计学意义(P<0.05)。结论阿奇霉素联合甲泼尼龙治疗难治性支原体肺炎的效果得以充分论证,能改善患者的临床症状,降低炎症反应,具有较高的临床应用价值。

objective To explore the clinical effect of Azithromycin combined with Methylprednisolone in the treatment of refractory Mycoplasma pneumonia.Methods A total of 46 patients with refractory Mycoplasma pneumonia admitted to our hospital from June 2016 to June 2019 were selected as the research subjects,and they were grouped according to the random number table method.The 23 patients in the reference group were treated with Azithromycin,and the 23 patients in the study group were treated with Azithromycin combined with Methylprednisolone.Serum inflammatory factors such as high-sensitivity C-reactive protein(hs-CRP),serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),as well as the total number of T lymphocytes(CD3+),negative T cells(CD4+),positive T cells(CD8+)and the ratio of negative T cells to positive T cells(CD4+/CD8+)peripheral blood indexes were compared and analyzed,and the clinical efficacy of the two groups was observed.Results After treatment,the levels of hs-CRP,TNF-αand IL-6 in the two groups were lower than those in this group before treatment,and the differences were statistically significant(P<0.05).The levels of hs-CRP,TNF-αand IL-6 in the study group were lower than those in the reference group after treatment,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+of the two groups were higher than those in this group before treatment,and the level of CD8+was lower than that in this group before treatment,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the study group were higher than those in the reference group,and the level of CD8+was lower than that in the reference group,the differences were statistically significant(P<0.05).The total effective rate of treatment in the study group was higher than that in the reference group,the difference was statistically significant(P<0.05).Conclusion The effect of Azithromycin combined with Methylprednisolone in the treatment of refractory Mycoplasma pneumonia has been fully demonstrated,which can improve the clinical symptoms of patients and reduce inflammation,and has high clinical application value.